Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

187 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.
Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. Hirsch MS, et al. Among authors: loveday c. Clin Infect Dis. 2003 Jul 1;37(1):113-28. doi: 10.1086/375597. Epub 2003 Jun 23. Clin Infect Dis. 2003. PMID: 12830416
Drug resistance mutations in HIV-1.
D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. D'Aquila RT, et al. Among authors: loveday c. Top HIV Med. 2003 May-Jun;11(3):92-6. Top HIV Med. 2003. PMID: 12837968 Free article. No abstract available.
Drug Resistance Mutations in HIV-1.
D'Aquila RT; International AIDS Society-USA; Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. D'Aquila RT, et al. Among authors: loveday c. Top HIV Med. 2002 Nov-Dec;10(5):21-25. Top HIV Med. 2002. PMID: 12717052 Free article. No abstract available.
Resistance and virological response analyses in a three initial treatment strategy trial: a substudy of the INITIO trial.
Descamps D, Chazallon C, Loveday C, Bacheler L, Goodall R, Yéni P, Cooper DA, Babiker A, Aboulker JP, Brun-Vézinet F; Nitio Trial International Coordinating Committee. Descamps D, et al. Among authors: loveday c. HIV Clin Trials. 2009 Nov-Dec;10(6):385-93. doi: 10.1310/hct1006-385. HIV Clin Trials. 2009. PMID: 20133269 Clinical Trial.
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, Sabin CA, Doerr HW, Johnson MA, Loveday C, Miller V; Royal Free Centre for HIV Medicine; Goethe Universität Clinic Cohort. Phillips AN, et al. Among authors: loveday c. J Infect Dis. 2002 Oct 15;186(8):1086-91. doi: 10.1086/343801. Epub 2002 Sep 30. J Infect Dis. 2002. PMID: 12355358 Free article.
187 results